Evaxion A EVAX
NASDAQ EVAX
$3.31 +0.03 (+0.91%)
At close: Aug 21, 2026 · 4:00 PM EDT

Evaxion A (EVAX) Cash from Financing Activities (2020 - 2022)

Evaxion A's (EVAX) quarterly Cash from Financing Activities came in at -$300000.0 in Q2 2022, down 101.19% YoY from $25.2 million in Q2 2021, and down 103.88% on a QoQ basis from $7.7 million in Q1 2022.

Evaxion A (EVAX) Cash from Financing Activities (2020 - 2022) Analysis & Trends

Evaxion A (EVAX) has 3 years of Cash from Financing Activities data on file, last reported at -$300000.0 in Q2 2022.

  • Quarterly Cash from Financing Activities fell 101.19% year-over-year to -$300000.0 in Q2 2022, while the trailing twelve-month figure through Jun 2022 was $57.8 million (up 1.64% YoY) and the FY2025 annual result came in at $22.4 million, up 70.69% from the prior year.
  • Cash from Financing Activities retreated to -$300000.0 in Q2 2022, from $7.7 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $25.3 million in Q1 2021 to a low of -$300000.0 in Q2 2022.
  • A 3-year average of $11.2 million and a median of $7.1 million in 2020 frame the typical range for Cash from Financing Activities.
  • Annual changes were most pronounced in 2021 — Cash from Financing Activities jumped 140388.89% — and 2022, when it plunged 101.19%.
  • Tracing EVAX's Cash from Financing Activities over 3 years: stood at $6.4 million in 2020, then soared by 290.38% to $25.2 million in 2021, then sank by 101.19% to -$300000.0 in 2022.
  • The last three Cash from Financing Activities figures came in at -$300000.0 (Q2 2022), $7.7 million (Q1 2022), and $25.2 million (Q3 2021), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn -426.70 Mn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn -1.22 Bn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn -
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn 14.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn -6.05 Mn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn 36.24 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn -16.65 Mn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn 27.18 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn - -273.15 Mn
10 Evaxion A 27.61 Mn 27.61 Mn - -

Historic Data

Download Data
DateValue
Jun 30, 2022 -300,000.00
Jun 30, 2022 -300,000.00
Mar 31, 2022 7.74 Mn
Mar 31, 2022 7.74 Mn
Sep 30, 2021 25.15 Mn
Sep 30, 2021 25.15 Mn
Jun 30, 2021 25.22 Mn
Jun 30, 2021 25.22 Mn
Mar 31, 2021 25.25 Mn
Mar 31, 2021 25.25 Mn
Sep 30, 2020 6.44 Mn
Sep 30, 2020 6.44 Mn
Jun 30, 2020 -36,000.00
Jun 30, 2020 -36,000.00
Mar 31, 2020 -18,000.00
Mar 31, 2020 -18,000.00